anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a skin cosmetic excellent in safety, light stability and ultra violet light-absorbing effect, containing an extract from the roots of a Rutaceae Juss. CONSTITUTION: This skin cosmetic contains, as active ingredient, 0.005-30wt.%, on a dry basis, of at least one kind of liquid extract derived from the roots of a Rutaceae Juss., esp. Murraya paniculata Jack., Murraya koenigii Spreng., Murraya coloxylon Ridl. and/or Murraya euchrestifolia Hayata, each belonging to Murraya Koen. ex L. Besides, the cosmetic is incorporated, as necessary, with conventionally used various ingredients, aqueous ingredient, humectant, thickening agent, antiseptic agent, antioxidant, perfume, coloring matter, medicinal agent, etc., in the form of liquid, milky lotion, cream or stick. The extraction is conducted by the following process: each of the above plants is subjected to extraction with an organic solvent (e.g., methanol) followed by distilling the solvent off and then, as necessary, purification by active carbon, column chromatography, etc.  The extract thus obtained can absorb ultraviolet light with wavelengths of UV-A and/or UV-B region(s).
BACKGROUND: Predicting cognitive decline among individuals in the aging population who are already amyloid-β (Aβ) positive or tau positive poses clinical challenges. In Alzheimer's disease research, intra-default mode network (DMN) connections play a pivotal role in diagnosis. In this article, we propose metabolic connectivity within the DMN as a supplementary biomarker to the Aβ, pathological tau, and neurodegeneration framework.
METHODS: Extracting data from 1292 participants in the Alzheimer's Disease Neuroimaging Initiative, we collected paired T1-weighted structural magnetic resonance imaging and 18F-labeled-fluorodeoxyglucose positron emission computed tomography scans. Individual metabolic DMN networks were constructed, and metabolic connectivity (MC) strength in the DMN was assessed. In the cognitively unimpaired group, the Cox model identified cognitively unimpaired (MC+), high-risk participants, with Kaplan-Meier survival analyses and hazard ratios revealing the strength of MC's predictive performance. Spearman correlation analyses explored relationships between MC strength, and Aβ, pathological tau, neurodegeneration biomarkers, and clinical scales. DMN standard uptake value ratio (SUVR) provided comparative insights in the analyses.
RESULTS: Both MC strength and SUVR exhibited gradual declines with cognitive deterioration, displaying significant intergroup differences. Survival analyses indicated enhanced Aβ and tau prediction with both metrics, with MC strength outperforming SUVR. Combined MC strength and Aβ yielded optimal predictive performance (hazard ratio = 9.29), followed by MC strength and tau (hazard ratio = 8.92). Generally, the strength of MC's correlations with Aβ, pathological tau, and neurodegeneration biomarkers exceeded SUVR.
CONCLUSIONS: Individuals with normal cognition and disrupted DMN metabolic connectivity face an elevated risk of cognitive decline linked to Aβ that precedes metabolic issues.
There has been little very early (after Emergency Department presentation) hemodynamic monitoring of acutely ill or injured patients secondary to the lack of non invasive technologies that could be reliably applied to this patient population.Thus all assessments of hemodynamics have been made by physicians on clinical information including intermittent pulse and blood pressure measurements. It is not known what the underlying continuous cardiac output, systemic vascular resistance, etc are in these patients and how these change with current Emergency Medicine therapeutic interventions. Currently there is available a finger cuff devise (NexfinHD Monitor, BMEYE, Amsterdam) that can measure these hemodynamics on a beat to beat basis and that can be easily applied to acutely ill individuals. This prospective pilot study of 48 patients (4 groups of 12 each) will document the hemodynamics of patients on arrival and continuously for 2 hours, blinded to the treating physician. Treating physicians will be asked to estimate these hemodynamic parameters at various time points. The study will characterize the hemodynamics of patients, compare them to the estimates of treating physicians and determine whether they predict the need for life saving interventions.
PURPOSE: To prepare the titled composition having bactericidal effect esp. to bacteria belonging to Micrococcus genus, and useful for the slime control in paper-making process, by using 4,5-dichloro-1,2-dithiol-3-one and an alkylene bisthiocyanate as active components.  
     CONSTITUTION: The objective composition contains (A) 4,5-dichloro-1,2-dithiol-3- one and (B) an alkylene bisthiocyanate. The weight ratio of (A):(B) is pref. 1:(0.1W25). It is applied in the form of a liquid agent, etc. by using a hydrophilic organic solvent such as diethylene glycol monomethyl ether, etc. For the application to the paper-making process, it is preferable to apply in the form of a liquid agent using the above hydrophilic organic solvent and a dispersant, wherein said liquid agent is composed of pref. 1W50pts.wt. of the active components, 0.05W1.0pt. of dispersant per 1pt. of the active components, and the remaining pts. of the solvent. 
     COPYRIGHT: (C)1982,JPO&Japio
###  Risk Summary

Cetirizine has been reported to be excreted in human breast milk following oral administration. Multiple doses of oral dose cetirizine (10 mg tablets once daily for 10 days) resulted in systemic levels (Mean C max = 311 ng/mL) that were 100 times higher than the observed human exposure (Mean C max = 3.1 ng/mL) following twice-daily administration of cetirizine ophthalmic solution 0.24% to both eyes for one week [see Clinical Pharmacology ( 12.3)] . Comparable bioavailability has been found between the tablet and syrup dosage forms. However, it is not known whether the systemic absorption resulting from topical ocular administration of ZERVIATE could produce detectable quantities in human breast milk. 

There is no adequate information regarding the effects of cetirizine on breastfed infants, or the effects on milk production to inform risk of ZERVIATE to an infant during lactation. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ZERVIATE and any potential adverse effects on the breastfed child from ZERVIATE.
Caregiver participants will receive Ceresti's Caregiver-Enabled Care Program. (CECP) is a 6-month non-medical digital program that promotes the wellness of family caregivers, and increases their knowledge, skills and confidence ("activation") in caring for a loved one with dementia. CECP delivers personalized health education, access to resources, proactive coaching, personalized support, and remote monitoring via a dedicated tablet that is shipped to the caregiver's home.
Background: IL-1β plays a critical role in the pathophysiology of neuroinflammation. The presence of cleaved IL-1β (cIL-1β) in the neurons of the dorsal root ganglion (DRG) implicates its function in biological signaling arising from the sensory neuron. This study was conducted to analyze the role of IL-1β in nociceptive transduction after tissue injury. Methods: A plantar incision was made in C57BL/6 mice, following which immunohistochemistry and RNA scope in situ hybridization were performed at various time points to analyze cIL-1β, caspase-1, and IL-1 receptor 1 (IL-1R1) expression in the DRG. The effect of intrathecal administration of a caspase-1 inhibitor or regional anesthesia using local anesthetics on cIL-1β expression and pain hypersensitivity was analyzed by immunohistochemistry and behavioral analysis. ERK phosphorylation was also analyzed to investigate the effect of IL-1β on the activity of spinal dorsal horn neurons. Results: cIL-1β expression was significantly increased in caspase-1-positive DRG neurons 5 min after the plantar incision. Intrathecal caspase-1 inhibitor treatment inhibited IL-1β cleavage and pain hypersensitivity after the plantar incision. IL-1R1 was also detected in the DRG neurons, although the majority of IL-1R1-expressing neurons lacked cIL-1β expression. Regional anesthesia using local anesthetics prevented cIL-1β processing. Plantar incision-induced phosphorylation of ERK was inhibited by the caspase-1 inhibitor. Conclusion: IL-1β in the DRG neuron undergoes rapid cleavage in response to tissue injury in an activity-dependent manner. Cleaved IL-1β causes injury-induced functional activation of sensory neurons and pain hypersensitivity. IL-1β in the primary afferent neurons is involved in physiological nociceptive signal transduction.
A dispenser (10) for delivering a beneficial agent formulation (18) to a warm, fluid environment of use comprises an outer semipermeable wall (12) surrounding and laminating an inner hydrophilic, swellable wall (15) which defines an interior space (14) for containing a thermo-responsive beneficial agent formulation. A passageway (13) through the semipermeable wall connects the exterior of the dispenser through an opening in the inside wall with the interior of the dispenser. The drug composition contained in the dispenser preferably melts at body- temperature. The inside wall (15) may be formed of a hydrogel polymer eg. poly-(hydroxyalkyl methacrylate). The outer wall (12) may be a cellulosic polymer such as an ester or ester-ether. <IMAGE>
Telemental health START will deliver two components via telephonic or other communication technology (e.g., Zoom). This includes component #2 (consultation and coping skills coaching) and component #4 (service linkages, referrals, outreach, \& training). START components #1 (intake and quarterly assessment) and #3 (24-hour urgent crisis response and intervention) will continue to be provided in-person.
<P>PROBLEM TO BE SOLVED: To obtain a polyphenol solution of transplantation immunoreaction inhibition for suppressing both a graft rejection and a graft-versus-host disease and to provide a method for suppressing a transplantation immunoreaction using the same.  <P>SOLUTION: The polyphenol solution of transplantation immunoreaction inhibition has a polyphenol and a liquid to dissolve the polyphenol. The polyphenol is attached to an antigen determination group of a graft of cells, tissue, organ, etc., to suppress development of graft rejection, graft-versus-host disease, etc., being an immunoreaction between a graft and a host. The transplantation immunoreaction inhibition method comprises immersing a graft before transplantation in a polyphenol solution of a transplantation immunoreaction inhibition. (-)-Epigallocatechin-3-O-gallate (EGCG) is suitable as a polyphenol being an active ingredient.  <P>COPYRIGHT: (C)2007,JPO&INPIT
T2D patients and controls in the experimental group will undergo 50 telemedicine MOS sessions (15 minutes/day, 5 days/week, 10 weeks). Before the training period all subjects will participate to three different experimental sessions: during the first session a blood sample will be withdrawn and a skin biopsy will be taken; during the second session, muscle-tendon stiffness and muscle function will be evaluated; during the third session, the energy cost of walking will be determined at different speeds. After the training period and 5 weeks after the end of the training period, all subjects will repeat the second and the third sessions.
The RUNX1 gene, located at chromosomal band 21q22, is a transcription factor, crucial for hematopoiesis and the generation of hematopoietic stem cells in the embryo. RUNX1 is the most frequent target for chromosomal translocation in leukemia. In addition, point mutations in the RUNX1 gene have been found to constitute an important mode of genetic alteration in development of leukemia. Recent publications stressing the clinical need for implementing RUNX1 point mutations as both a diagnostic and unfavorable prognostic marker of AML, have aroused particular interest in the functional role of RUNX1 in this disease.

In order to pinpoint specific RUNX1 target genes involved in pre-leukemic transformation or exacerbation of existing leukemia, the investigators plan to compare expression profiles from human hematopoietic progenitors overexpressing a mutated form of RUNX1with controls (RUNX1 wild-type and knocked-down). In this study the investigators intend to collect blood, after receiving informed consent, from umbilical cords of neonates born vaginally, in order to isolate CD34+ hematopoietic progenitors. Human umbilical cord blood contains relatively high numbers of CD34+ cells, which may be frozen directly after collection and used as a source of progenitor cells for further culture or direct analysis.
Participants will receive a 15-week behavioral weight loss program which teaches strategies for changing diet and exercise behaviors. This will consist of a combination of group and individual sessions. Group classes will be delivered remotely via a video-conferencing platform. This will be followed by an 8-week mindfulness-based self-compassion program which combines the skills of mindfulness and self-compassion as a means for improving emotional resilience, well-being, and weight control.
BACKGROUND: The Proximal Femur Maturity Index (PFMI) can be used to assess skeletal maturity on existing whole-spine radiographs without additional radiation. However, the relationship between the PFMI at the initiation of bracing for adolescent idiopathic scoliosis (AIS) and subsequent curve progression remains unknown. This study aimed to investigate the relationship between the PFMI and curve progression, and the predictability of risks to adulthood curve progression and surgical thresholds based on the PFMI grade at brace initiation.
METHODS: This was a prospective study of 202 patients with AIS who were prescribed underarm bracing according to the Scoliosis Research Society criteria and had good brace-wear compliance. The patients were followed from brace initiation until complete skeletal maturity. Longitudinal data on the coronal Cobb angle and skeletal maturity assessments using Risser staging, Sanders staging, the distal radius and ulna classification, and the PFMI were collected. Each patient was assessed on whether the major curve progressed to ≥40° (adulthood deterioration) and ≥50° (the surgical threshold). Logistic regressions were used to predict probabilities of curve progression to the 2 thresholds, adjusted for factors that were significant in univariate analyses.
RESULTS: The PFMI correlated with the other skeletal maturity indices (r s [Spearman rank correlation] = 0.60 to 0.72, p < 0.001 for all). The pre-brace PFMI grade correlated with progression to ≥40° (r rb [rank-biserial correlation] = -0.30, p < 0.001) and to ≥50° (r rb = -0.20, p = 0.005). Based on regression models (p < 0.001) adjusted for the pre-brace major Cobb angle and curve type, brace initiation at PFMI grades 2 and 3 for a curve of ≥30° had predicted risks of 30% (95% confidence interval [CI], 4% to 55%) and 12% (95% CI, 7% to 17%), respectively, for progression to the surgical threshold. Brace initiation at PFMI grade 5 had 0% progression risk.
CONCLUSIONS: The PFMI can be used for predicting curve progression and prognosticating brace outcomes in AIS. Patients with brace initiation at PFMI grade 4 for a curve of <30° or at grade 5 were unlikely to progress to the adulthood deterioration or surgical threshold. In comparison, skeletally immature patients initiating bracing at a PFMI grade of ≤3 for a major curve of ≥30° had a higher risk of progression despite compliant brace wear.
LEVEL OF EVIDENCE: Prognostic Level II . See Instructions for Authors for a complete description of levels of evidence.
PURPOSE:To achieve a higher detection capacity along with a simplified process, by detecting and estimating material to be inspected using an adjusting factor of enzyme activity to eliminate the need for the separation (B/F separation) of the antigen and the antibody bonded from the antigen or the antibody being isolated. CONSTITUTION:For example, glutathione reductase (NADPH) as apoenzyme and flavine adenine nucleotide (FAD) belonging to a prosthetic group as adjusting factor are used to detect material 3 to be inspected. First, the FAD 2 which is sensitized with an antibody adapted to be bonded specifically to and reacted with the material 3 being inspected with the addition of a buffer liquid is prepared into a test tube 1 and a sample of serum or the like containing the material 3 being inspected. Then, the material 3 being inspected and the antibody sensitize to the FAD 2 are subjected to an antigen-antibody reaction and the NADPH is added to the test tube 1 as apoenzyme. The apoenzyme 4 is not integrated with the FAD 2 bonded to the material 3 being inspected but specifically done with the FAD 2 not integrated with the material 3 being inspected. As the apoenzyme 4 is activated as integrated with the FAD 2, the material 3 being inspected an be estimated by determining the activity value of the apoenzyme 4.
The invention rovides 4-amino-4-oxobutanoyl peptide compounds of FormulaI (I) and the pharmaceutically salts and hydrates thereof. The variables R1-R9,R16, R18 R19, n, M,, n, M,, and Z are defined herein. Certain compounds of FormulaI are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compoundsdisclosed herein are potent and/ or selective inhibitors of viral replication,particularly Hepatitis C virus replication. The invention also provides pharmaceuticalcompositions containing one or more 4-amino-4-oxobutanoyl peptide compoundsand one or more pharmaceutically acceptable carriers. Such pharmaceuticalcompositions may contain 4-amino-4-oxobutanoyl peptide compound as the onlyactive agent or may contain a combination of 4-amino-4-oxobutanoyl peptidecontaining peptides compound and one or more other pharmaceutically activeagents. The invention also provides methods for treating viral infections,including Hepatitis C infections, in mammals.
By definition, Eosinophil Esophagitis involves the presence of eosinophils in the esophageal mucosa. Although incompletely understood, the pathophysiology of Eosinophil Esophagitis is thought to include food allergen driven inflammation in the esophageal mucosa that triggers release of mediators for recruitment of eosinophils. The mediators, such as eotaxin, invoke eosinophil activation and trafficking into the esophageal tissue. The subsequent release of mediators from eosinophils and other cells, including mast cells and basophils, promotes inflammation and fibrosis resulting in Eosinophil Esophagitis symptoms. This protocol focuses on early eosinophil activation events in Eosinophil Esophagitis in the peripheral circulation, specifically activation of surface β1 integrin, as a biomarker for disease activity reflecting eosinophils destined for trafficking into the esophagus. Demonstrating a correlation between disease activity and a peripheral biomarker may ultimately facilitate a timelier, less invasive and less costly management strategy for Eosinophil Esophagitis.
INTRODUCTION: Intraosseous (IO) infusion, the pressurized injection of fluids into bone through a catheter, is a life-preserving resuscitative technique for treating trauma patients with severe hemorrhage. However, little is known regarding the application times, placement accuracy, and end-user ratings of battery-powered and manual IO access devices. This study was specifically designed to fill these knowledge gaps on six FDA-approved IO access devices.
MATERIALS AND METHODS: Three experienced U.S. Navy Emergency Medicine residents each placed commercially available 15-gauge IO catheters in cadaveric swine (Sus scrofa) proximal humeri and sternums in a randomized prospective experimental design. Devices included the battery-powered EZ-IO Rapid Infuser and the manual Jamshidi IO, PerSys NIO, SAM Manual IO, Tactical Advanced Lifesaving IO Needle (TALON), and PYNG First Access for Shock and Trauma 1 (30 trials per device, 10 per user, 210 total trials). Application times, placement accuracy in medullary (zone 1) and trabecular (zone 2) bone while avoiding cortical (zone 3) bone, and eight subjective user ratings were analyzed using ANOVA and nonparametric statistics at P < .05.
RESULTS: The EZ-IO demonstrated the fastest application times, high rates in avoiding zone 3, and the highest user ratings (P < .0001). The TALON conferred intermediate placement times, highest rates of avoiding zone 3, and second-highest user ratings. The SAM Manual IO and Jamshidi performed poorly, with mixed results for the PerSys NIO and PYNG First Access for Shock and Trauma 1.
CONCLUSIONS: The battery-powered EZ-IO performed best and remains the IO access device of choice. The present findings suggest that the TALON should be considered as a manual backup to the EZ-IO.
Contemporary antiobesity medications (AOMs) are highly efficacious for the treatment of obesity and obesity-related comorbidities. Given this effectiveness, lifestyle factors within the context of AOM treatments need to refocus and move away from efforts to enhance weight loss. Rather, lifestyle considerations should pivot to being complementary to the benefits realized with AOM treatment and be redirected to enhancing holistic patient health and well-being. Physical activity is an important lifestyle behavior that contributes to many health benefits both in conjunction with, and in the absence of, weight loss. Physical activity improves cardiorespiratory fitness, muscle strength, and physical function. Physical activity may attenuate the loss of lean mass that is observed with AOM treatments and may enhance the quality and function of muscle. Physical activity is a key behavior for holistic health within this era of contemporary AOMs that warrants appropriate attention within the clinical care of patients.
Use of a at least one type of xanthophylls for the preparation of a medicament for prophylactic and/or therapeutic treatment of dyspepsia, is disclosed. The xanthophyll is preferably astaxanthin, e.g. astaxanthin is in a form esterified with fatty acids, such as in algal meal prepared from a culture of the alga  Haematococcus  sp. The medicament may further comprise carbohydrate structures and/or (a) different antioxidant(s). Further, a method of prophylactic and/or therapeutic treatment of dyspepsia in an individual, is described. The method comprises administration to said individual of an dyspepsia-alleviating amount of a medicament comprising at least one type of xanthophylls.
There have been post-marketing reports of severe skin and hepatic adverse events associated with griseofulvin use (see WARNINGS section).

When adverse reactions occur, they are most commonly of the hypersensitivity type, such as skin rashes, urticaria, and rarely, angioneurotic edema, and erythema multiforme. These may necessitate withdrawal of therapy and appropriate countermeasures. 

Peripheral neuropathy and paresthesias of the hands and feet have been reported and may be related to treatment duration. Most patients treated with griseofulvin for less than six months experienced improvement or resolution of their neuropathy upon withdrawal of the griseofulvin. Other side effects reported occasionally are oral thrush, nausea, vomiting, epigastric distress, diarrhea, headache, fatigue, dizziness, insomnia, mental confusion and impairment of performance of routine activities.

Proteinuria, nephrosis (sometimes associated with existing systemic lupus erythematosus), leukopenia, coagulopathy, hepatitis, elevated liver enzymes, hyperbilirubinemia, and GI bleeding have been reported rarely. Administration of the drug should be discontinued if granulocytopenia occurs.